Nasal foralumab for non-active secondary progressive MS
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a nasal spray medication, foralumab, to see if it can help people with non-active secondary progressive multiple sclerosis. It is only for people who completed a previous related study (TILS-021).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the previous TILS-021 study within the last 90 days.
- Your blood counts (hemoglobin, platelets), kidney and liver function must be within safe levels.
- You cannot have used certain MS treatments (like fingolimod, ocrelizumab) recently or plan to start them during the study.
- You must avoid pregnancy during the study and for 90 days afterward if you are able to get pregnant or have a partner who can.
- You cannot have serious nasal problems, active infections, a history of certain cancers, or other major medical conditions listed by the study doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study provides access to an experimental nasal spray medication called foralumab for people with a specific type of MS that has stopped responding to standard treatments. The goal is to see if the drug can slow or stop disability progression.
This trial tests a nasal spray called Foralumab for people with multiple system atrophy (MSA). The goal is to see if the spray can help reduce symptoms or slow the disease. It is for people who are otherwise healthy enough to safely participate.
This study tests an experimental drug called Foralumab, which aims to calm overactive immune cells in the brain linked to Alzheimer's. It may help slow memory loss in people with early-stage Alzheimer's.
This study tests a new nasal spray medicine called foralumab to see if it is safe and can slow down ALS. The trial is part of the Healey ALS platform and uses special scans to check how the medicine affects the brain.
This study tests a nasal spray form of the steroid methylprednisolone for treating MS relapses. The goal is to see if this new way of taking the medicine works as well or better than standard treatments.
This study tests a new treatment that combines a type of immune cell therapy with a targeted antibody to see if it can help people with multiple sclerosis. It aims to reduce the immune system's attack on the nervous system and potentially slow disease progression.
Hear when a new Non-Active Secondary Progressive Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.